RE:What does this do to the relationship with Ipsen? Likely unaffected .... Their partnership with IPSEN was to release MCNA outside of the USA (and a few other regions).
PARIS and MONTREAL, Oct. 28, 2015 /CNW Telbec/ - Ipsen (Euronext: IPN) (ADR: IPSEY) and Telesta Therapeutics Inc. (TSX: TST) (PNK: BNHLF) today announced that they have entered into an exclusive licensing agreement for Ipsen to develop and commercialize MCNA1 for the treatment of high risk non-muscle invasive bladder cancer (NMIBC) in all countries of the world, with the exception of the United States, where Telesta is establishing commercial operations, Canada, South Africa, Mexico, South Korea and Japan.
Telesta recently filed a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for MCNA for the treatment of high risk non-muscle invasive bladder cancer patients who are refractory or relapsing from BCG front-line treatment. The FDA has assigned priority review to Telesta's BLA with a review (PDUFA) date of February 27, 2016. Telesta retains full and sole ownership of MCNA rights in the US and Japan and will be responsible for the commercial launch of MCNA in the United States while Ipsen will initiate discussions with regulatory authorities to identify the regulatory path and potential requirements for the product in Europe and other key licensed territories.
Read more at https://www.stockhouse.com/news/press-releases/2015/10/28/telesta-therapeutics-and-ipsen-announce-exclusive-license-agreement-for-mcna-1#6SkJK4FUk2MtPvf6.99